ANTIPROTEINURIC EFFECT OF SPARSENTAN, A DUAL ANGIOTENSIN II AND ENDOTHELIN TYPE A RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A SUBGROUP ANALYSIS OF THE DUET TRIAL

被引：0
|
作者：
Gesualdo, Loreto [1 ]
Lieberman, Kenneth [4 ]
Tesar, Vladimir [2 ]
Srivastava, Tarak [3 ]
Komers, Radko [5 ]
机构：
[1] Azienda Osped Univ Consorziale, Nephrol Dialysis & Transplantat Unit, Bari, Italy
[2] Charles Univ Prague, Nephrol, Prague, Czech Republic
[3] Childrens Mercy Hosp, Nephrol, Kansas City, MO 64108 USA
[4] Hackensack Univ, Med Ctr, Nephrol, Hackensack, NJ USA
[5] Retrophin, Clin, Cambridge, MA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2017年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
TO042
引用
收藏
页数：1
相关论文
共 10 条
  • [1] NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL
    Trachtman, Howard
    Rychlik, Ivan
    Haws, Robert
    Nester, Carla
    Fornoni, Alessia
    Komers, Radko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [2] Sparsentan Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist Treatment of focal segmental glomerulosclerosis Treatment of IgA nephropathy
    Trachtman, H.
    Hogan, J. J.
    Tesar, V
    Komers, R.
    DRUGS OF THE FUTURE, 2020, 45 (02) : 79 - 98
  • [3] Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
    Komers, Radko
    Gipson, Debbie S.
    Nelson, Peter
    Adler, Sharon
    Srivastava, Tarak
    Derebail, Vimal K.
    Meyers, Kevin E.
    Pergola, Pablo
    MacNally, Meghan E.
    Hunt, Jennifer L.
    Shih, Alvin
    Trachtman, Howard
    KIDNEY INTERNATIONAL REPORTS, 2017, 2 (04): : 654 - 664
  • [4] The dual endothelin A and angiotensin II type 1 receptor antagonist sparsentan (FILSPARI®) exhibits a safe nonclinical male fertility toxicity profile
    Bedard, Patricia W.
    Pretto, Francesca
    Patel, Sima
    Jenkinson, Celia
    White, Tacey
    Kohan, Donald E.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2025, 156
  • [5] Glomerulomegaly predicts a poor response to steroid therapy but a sufficient antiproteinuric effect of renin-angiotensin system (RAS) blockade in patients with primary focal glomerulosclerosis (FSGS).
    Ishii, T
    Utsunomiya, Y
    Ogura, M
    Shimada, T
    Kawamura, T
    Hosoya, T
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 265A - 265A
  • [6] Pretransplant Anti-Angiotensin Type 1 Receptor Antibodies (Anti-AT1R) Can Predict Patients at High Risk of Post-Transplant Focal Segmental Glomerulosclerosis (FSGS) Recurrence
    Mujtaba, M.
    Taber, T.
    Goggins, W.
    Kassis, N.
    Yaqub, M.
    Khalil, A.
    Sher, J.
    Khalid, M.
    Sharfuddin, A.
    Book, B.
    TRANSPLANTATION, 2014, 98 : 530 - 530
  • [7] Pretransplant Anti-Angiotensin Type 1 Receptor Antibodies (Anti-AT1R) Can Predict Patients at High Risk of Post-Transplant Focal Segmental Glomerulosclerosis (FSGS) Recurrence.
    Mujtaba, M.
    Taber, T.
    Goggins, W.
    Kassis, N.
    Yaqub, M.
    Khalil, A.
    Sher, J.
    Khalid, M.
    Sharfuddin, A.
    Book, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 530 - 530
  • [8] Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade:: A short-term, randomized, controlled trial
    Navarro, JF
    Mora, C
    Muros, M
    García, J
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07): : 2119 - 2126
  • [9] Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism A Prospective Cohort Study in Primary Care
    Yajima, Ken
    Shimada, Akira
    Hirose, Hiroshi
    Oikawa, Yoichi
    Yamada, Satoru
    Meguro, Shu
    Irie, Junichiro
    Irie, Seiko
    CLINICAL DRUG INVESTIGATION, 2009, 29 (12) : 811 - 819
  • [10] Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose MetabolismA Prospective Cohort Study in Primary Care
    Ken Yajima
    Akira Shimada
    Hiroshi Hirose
    Yoichi Oikawa
    Satoru Yamada
    Shu Meguro
    Junichiro Irie
    Seiko Irie
    Clinical Drug Investigation, 2009, 29 : 811 - 819
1